CL2021000033A1 - Nuevos compuestos - Google Patents

Nuevos compuestos

Info

Publication number
CL2021000033A1
CL2021000033A1 CL2021000033A CL2021000033A CL2021000033A1 CL 2021000033 A1 CL2021000033 A1 CL 2021000033A1 CL 2021000033 A CL2021000033 A CL 2021000033A CL 2021000033 A CL2021000033 A CL 2021000033A CL 2021000033 A1 CL2021000033 A1 CL 2021000033A1
Authority
CL
Chile
Prior art keywords
new compounds
diseases
new
human
pharmaceuticals
Prior art date
Application number
CL2021000033A
Other languages
English (en)
Inventor
Michael Joseph Bishop
Vincent J Colandrea
Yuehu Li
Eugene L Stewart
Iulia Strambeanu
Katherine Louisa Widdowson
James Walter Janetka
Laurel Kathryn Mcgrane
Original Assignee
Glaxosmithkline Ip Dev Ltd
Fimbrion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd, Fimbrion Therapeutics Inc filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CL2021000033A1 publication Critical patent/CL2021000033A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen en la presente memoria nuevos compuestos y composiciones de C-manósido y su aplicación como productos farmacéuticos para el tratamiento de enfermedades humanas. También se proporcionan métodos para inhibir la actividad de FimH en un sujeto humano con el fin de tratar enfermedades, tales como infección del tracto urinario.
CL2021000033A 2018-07-10 2021-01-07 Nuevos compuestos CL2021000033A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862695993P 2018-07-10 2018-07-10
US201862755588P 2018-11-05 2018-11-05

Publications (1)

Publication Number Publication Date
CL2021000033A1 true CL2021000033A1 (es) 2021-07-30

Family

ID=67957191

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000033A CL2021000033A1 (es) 2018-07-10 2021-01-07 Nuevos compuestos

Country Status (24)

Country Link
US (3) US11111262B2 (es)
EP (1) EP3820856B9 (es)
JP (2) JP7309862B2 (es)
KR (1) KR20210031682A (es)
CN (1) CN112334455B (es)
AU (1) AU2019301946B2 (es)
BR (1) BR112021000370A2 (es)
CA (1) CA3105940A1 (es)
CL (1) CL2021000033A1 (es)
DK (1) DK3820856T3 (es)
ES (1) ES2928634T3 (es)
HR (1) HRP20221381T1 (es)
HU (1) HUE060140T2 (es)
IL (1) IL279993B2 (es)
LT (1) LT3820856T (es)
MX (1) MX2021000340A (es)
PH (1) PH12020551905A1 (es)
PL (1) PL3820856T3 (es)
PT (1) PT3820856T (es)
RS (1) RS63712B1 (es)
SG (1) SG11202011066XA (es)
TW (1) TWI821328B (es)
UY (1) UY38293A (es)
WO (1) WO2020012336A1 (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11560388B2 (en) 2019-03-19 2023-01-24 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic aza-benzothiophene and aza-benzofuran compounds
US11964977B2 (en) 2020-05-29 2024-04-23 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic heterocyclic compounds
US11999742B2 (en) 2021-11-01 2024-06-04 Boehringer Ingelheim Vetmedica Gmbh Substituted pyrrolo[1,2-b]pyridazines as anthelmintics

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3105940A1 (en) * 2018-07-10 2020-01-16 Glaxosmithkline Intellectual Property Development Limited C-mannoside compounds useful for the treatment of urinary tract infections
CN113461753B (zh) 2020-03-31 2023-05-23 郑计岳 2-炔基甘露糖衍生物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122602A (en) 1989-02-13 1992-06-16 Miles Inc. Chromogenic merocyanine enzyme substrates
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
DK0730601T3 (da) 1993-11-18 2005-06-06 Univ Washington Forbindelser og farmaceutiske præparater til behandling af profylakse af bakterieinfektioner
EP1192038B1 (en) 1999-06-28 2003-11-05 Lear Corporation Method of forming a blow-molded plastic part having a living hinge
WO2001010386A2 (en) 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
EP1303256B1 (en) 2000-06-09 2009-01-07 Baylor College of Medicine The combination of antimicrobial agents and bacterial interference to coat medical devices
AU2003274127A1 (en) 2003-10-08 2005-04-21 Innovaprotean, S.L. Compounds for the treatment of diseases associated with the formation of amyloid fibrils
EP1755619A2 (en) 2004-03-23 2007-02-28 VIB vzw Anti-adhesive compounds to prevent and treat bacterial infections
SE528382C2 (sv) 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
FR2876798A1 (fr) 2004-10-14 2006-04-21 Univ Clermont Auvergne Diagnostic et traitement de la maladie de crohn
WO2011050323A1 (en) 2009-10-22 2011-04-28 The Washington University Compounds and methods for treating bacterial infections
AU2010333017B2 (en) 2009-12-14 2016-06-16 University Of Basel Mannose derivatives as antagonists of bacterial adhesion
ES2732311T3 (es) 2011-02-07 2019-11-21 Univ Washington Compuestos de manósidos y procedimientos de uso de los mismos
WO2012164074A1 (en) 2011-06-03 2012-12-06 University Of Basel Mannose phosphate derivatives as antagonists of bacterial adhesion
US20130261077A1 (en) 2012-03-07 2013-10-03 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
EP2690105A1 (en) 2012-07-24 2014-01-29 Centre National De La Recherche Scientifique Mannose derivatives, a process for preparing the same and their uses as a drug
US20140107049A1 (en) 2012-10-04 2014-04-17 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
PL2935302T3 (pl) 2012-12-18 2018-12-31 Vertex Pharmaceuticals Incorporated Pochodne mannozy do leczenia infekcji bakteryjnych
CA2905019C (en) 2013-03-12 2021-07-06 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
WO2014194270A1 (en) 2013-05-30 2014-12-04 Washington University Compounds and methods for treating bacterial infections
JP6961572B2 (ja) 2015-08-05 2021-11-05 アンテローム 付着性大腸菌と関連する病状の処置に有用なマンノース誘導体
JP2019508504A (ja) * 2016-03-11 2019-03-28 フィンブリオン セラピューティックス， インコーポレイテッドＦｉｍｂｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 疾病の処置に有用なｃ−グリコシド化合物
CA3018345A1 (en) 2016-03-23 2017-09-28 Fimbrion Therapeutics, Inc. Mannose-derived antagonists of fimh useful for treating disease
AU2018351471A1 (en) 2017-10-16 2020-05-07 Enterome New tools for assessing FimH blockers therapeutic efficiency
CA3105940A1 (en) * 2018-07-10 2020-01-16 Glaxosmithkline Intellectual Property Development Limited C-mannoside compounds useful for the treatment of urinary tract infections

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11560388B2 (en) 2019-03-19 2023-01-24 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic aza-benzothiophene and aza-benzofuran compounds
US11964977B2 (en) 2020-05-29 2024-04-23 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic heterocyclic compounds
US11999742B2 (en) 2021-11-01 2024-06-04 Boehringer Ingelheim Vetmedica Gmbh Substituted pyrrolo[1,2-b]pyridazines as anthelmintics

Also Published As

Publication number Publication date
RS63712B1 (sr) 2022-11-30
DK3820856T3 (da) 2022-10-24
AU2019301946B2 (en) 2022-03-31
US11697665B2 (en) 2023-07-11
IL279993B1 (en) 2023-09-01
JP7309862B2 (ja) 2023-07-18
EP3820856B9 (en) 2023-07-12
JP2022511594A (ja) 2022-02-01
JP7483820B2 (ja) 2024-05-15
US20230287028A1 (en) 2023-09-14
TWI821328B (zh) 2023-11-11
CN112334455A (zh) 2021-02-05
SG11202011066XA (en) 2021-01-28
UY38293A (es) 2020-05-29
WO2020012336A1 (en) 2020-01-16
HRP20221381T1 (hr) 2023-01-06
HUE060140T2 (hu) 2023-02-28
PT3820856T (pt) 2022-10-17
PL3820856T3 (pl) 2022-12-19
BR112021000370A2 (pt) 2021-04-06
PH12020551905A1 (en) 2021-06-21
ES2928634T3 (es) 2022-11-21
CN112334455B (zh) 2022-07-01
TW202019893A (zh) 2020-06-01
JP2022191325A (ja) 2022-12-27
MX2021000340A (es) 2021-03-25
IL279993A (en) 2021-03-01
AU2019301946A1 (en) 2020-11-26
EP3820856A1 (en) 2021-05-19
EP3820856B1 (en) 2022-08-31
US11111262B2 (en) 2021-09-07
US20210395287A1 (en) 2021-12-23
CA3105940A1 (en) 2020-01-16
KR20210031682A (ko) 2021-03-22
IL279993B2 (en) 2024-01-01
LT3820856T (lt) 2022-11-10
US20210017212A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
CL2021000033A1 (es) Nuevos compuestos
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
NI201800124A (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112017017599A2 (pt) métodos para modular respostas imunológicas e inflamatórias pela administração de uma biomassa algal
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
CO2017003321A2 (es) Inhibidores de gingipaina de lisina
EA201490637A1 (ru) Растительные стероиды и их применения
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
BR112022003659A2 (pt) Composições e métodos de tratamento de doenças vasculares
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
MX2018011539A (es) Tratamiento de dolencias y enfermedades cutaneas asociadas a biopeliculas microbianas.
CR20110438A (es) Icam 1 soluble como biomarcador para predicción de respuesta terapéutica
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
AR107460A1 (es) Gabapentina oftálmica para el tratamiento de las úlceras corneales
NI201200196A (es) Agentes terapéuticos 976
BR112022008856A2 (pt) Terapia combinada para doenças musculares
MX2018013885A (es) Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3).
BR112021022281A2 (pt) Novos compostos